Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-world Observational Survey (ENAMOR) (P7-1.015)

Authors

Hari P. Miskin
Edward Fox (ORCID: https://orcid.org/0000-0003-0347-1839)
Peter Sportelli
Chris Garner

Institutions

CDG Therapeutics (United States) (US)

Publication Details

Journal: Neurology
Published: 2025-04-07
DOI: https://doi.org/10.1212/wnl.0000000000212153
Primary Topic: Biosimilars and Bioanalytical Methods
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-world Observational Survey (ENAMOR) (P7-1.015)

Hari P. Miskin, Edward Fox, Peter Sportelli, Chris Garner

Apr 7, 2025

Neurology

Biosimilars and Bioanalytical Methods

article

Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-world Observational Survey (ENAMOR) (P7-1.015)

Hari P. Miskin, Edward Fox, Peter Sportelli, Chris Garner

April 7, 2025article en

Abstract

No abstract available for this paper.

NeurologyVol. 104(7_Supplement_1)

CDG Therapeutics (United States) (US)

Zero hunger

Openalex Percentile: Top 92%

Biosimilars and Bioanalytical Methods

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-world Observational Survey (ENAMOR) (P7-1.015) — Hari P. Miskin, Edward Fox, et al. · Neurology (2025) | TGRS Research Map | TGRS